Clinical Trial Update: Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 follow-up trial evaluating the long-term safety and tolerability of talsaclidine in patients with Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Talsaclidine (Talsaclidine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: TERMINATED